55016-26-7Relevant academic research and scientific papers
Anti-influenza drug discovery: Structure-activity relationship and mechanistic insight into novel angelicin derivatives
Yeh, Jiann-Yih,Coumar, Mohane Selvaraj,Horng, Jim-Tong,Shiao, Hui-Yi,Kuo, Fu-Ming,Lee, Hui-Ling,Chen, In-Chun,Chang, Chun-Wei,Tang, Wen-Fang,Tseng, Sung-Nain,Chen, Chi-Jene,Shih, Shin-Ru,Hsu, John T.-A.,Liao, Chun-Chen,Chao, Yu-Sheng,Hsieh, Hsing-Pang
experimental part, p. 1519 - 1533 (2010/08/20)
By using a cell-based high throughput screening campaign, a novel angelicin derivative 6a was identified to inhibit influenza A. (H1N1) virus induced cytopathic effect in Madin-Darby canine kidney cell culture in low micromolar range. Detailed structure-activity relationship studies of 6a revealed that the angelicin scaffold is essential for activity in pharmacophore B, while meta-substituted phenyl/2-thiophene rings are optimal in pharmacophore A and C. The optimized lead 4-methyl-9-phenyl-8-(thiophene-2-carbonyl)-furo[2,3-h] chromen-2-one (8g, IC50 = 70 nM) showed 64-fold enhanced activity compared to the high throughput screening (HTS) hit 6a. Also, 8g was found effective in case of influenza A (H3N2) and influenza B virus strains similar to approved anti-influenza drug zanamivir (4). Preliminary mechanistic studies suggest that these compounds act as anti-influenza agents by inhibiting ribonucleoprotein (RNP) complex associated activity and have the potential to be developed further, which could form the basis for developing additional defense against influenza pandemics.
COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER
-
Page/Page column 35, (2009/12/27)
Coumarin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, and X are defined herein. Also disclosed is a method for treating cancer with coumarin compounds.
